<DOC>
	<DOCNO>NCT01886105</DOCNO>
	<brief_summary>The primary goal study examine tumor response radiation treatment via combination Samarium-153 EDTMP external beam radiotherapy .</brief_summary>
	<brief_title>Combination External Beam Radiotherapy With 153Sm-EDTMP Treat High Risk Osteosarcoma</brief_title>
	<detailed_description>DAY 1 Tracer dose 153Sm-EDTMP administration ( 1 mCi/kg ) SPECT/High-resolution CT 4 hour . SPECT/CT ( low resolution ) 24 48 hrs DAY 7 Individualized treatment dose 153Sm-EDTMP administration ( max 30 mCi/kg ) SPECT scan 4 , 24 48 hour DAY 21 ( 2 week follow treatment dose administration ) Auto-Stem cell infusion DAY 40 ( approximately two week stem cell rescue ) Initiate external beam radiation therapy upon count recovery One month follow completion therapy Response assessment repeat imaging ( CT/MRI , Tc-99m bone scan ) 18F-MISO/FDG PET</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>Patients must 13 65 year age , inclusive Must unresectable primary tumor metastasis Must measurable disease demonstrate positive Tc99m Bone Scan . Not lesion must positive bone scan . Creatinine clearance &gt; 70ml/min/1.73m2 ANC &gt; 500/mm3 Platelets &gt; 50,000/mm3 Life expectancy &gt; 8 week Karnofsky performance status &gt; 50 % Stem cell product collect prior infusion Samarium must available , either peripheral stem cell mobilization bone marrow harvest prior trial entry . Patient may pregnant breastfeeding . Patients receive prior radiotherapy area current active disease eligible .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteosarcoma</keyword>
	<keyword>Osteogenic Sarcoma</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Bone Cancer</keyword>
</DOC>